The translation of bio-innovation into novel healthcare products and technologies to improve patient outcomes is completely reliant on securing sufficient investment. Whilst many will argue investment trends are cyclical, this has been a challenging financing environment, particularly at the early stages of development for a very extended period. As a consequence, bio-entrepreneurs are having to be flexible in the types, geographies and cost of capital, but the underlying need for a robust, well-protected innovation remains critical. Kindly hosted by Mathys & Squire, the session will discuss what a modern-day innovation investment strategy requires. 

 

Agenda:
08.30 – Arrival and Networking
09.15 – Welcome
09.20 – Trends in global IP strategies to maximise investor attraction
          Craig Titmus, Partner and Martin McLean, Partner, Mathys & Squire
09.30 – Accessing non-dilutive funding 
          Speaker tbc
09.40 – Navigating the de-risking stack
          Speaker tbc
09.50 – Short company pitches and Q&A
10.30 – Networking
11.00 – Close

Registration:
This event is open to attendees from the following organisation types: 
•    Companies undertaking R&D in the life science companies 
•    Investors and analysts
•    Product development advisers
•    Technology Transfer Offices
•    Policy makers
•    Translational research academics
•    Media

Attendance is by invitation only with limited capacity. To request an invitation please email Tony Jones at [email protected].